RxSight vs STAAR Surgical
RXST and STAA side by side, both in measuring, analyzing, and controlling instruments; photographic, medical and optical goods; watches and clocks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RXST and STAA compare
STAAR Surgical is the larger company, worth 6.1 times as much as RxSight ($1.2B against $203M).
STAAR Surgical grew revenue faster over the last twelve months (51.3% versus −13.2% for RxSight).
STAAR Surgical keeps more of each dollar of sales as profit, with a net margin of 1.1% compared with −36.8% at RxSight.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RXST | STAA |
|---|---|---|
| Size and price | ||
| Market cap | $203M | $1.2B |
| Share price | $4.87 | $24.54 |
| Change, 1 year | −42.2% | −7.7% |
| Change, 5 years | −63.2% | −78.8% |
| Beta (5Y) | 1.07 | 1.50 |
| Employees | 461 | 957 |
| StockData Score | ||
| Total score | 10 | 10 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 2 (better) |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 351× |
| P/S | 1.6× (better) | 3.6× |
| P/B | 0.8× (better) | 3.4× |
| EV/EBITDA | – | 76.4× |
| FCF yield | −13.4% | −0.55% (better) |
| Fair value | $20.54 | $15.38 |
| Margin of safety | 76.3% (better) | −59.6% |
| Growth | ||
| Revenue growth (TTM) | −13.2% | 51.3% (better) |
| Revenue growth, 5Y average | 55.7% (better) | 7.9% |
| Profitability | ||
| Gross margin | 77.5% (better) | 76.6% |
| Operating margin | −43.2% | 4.0% (better) |
| Net margin | −36.8% | 1.1% (better) |
| FCF margin | −21.3% | −2.0% (better) |
| Return on equity | −17.3% | 1.1% (better) |
| Return on invested capital | −82.9% | 4.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −3674.3× | – |
| Current ratio | 4.07 | 4.66 (better) |
| Altman Z-score | −0.69 | 7.82 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −0.99% | – |
| Shareholder yield | −0.99% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 99.6% | 110% |
| Held by insiders | 5.4% | – |
| Insider net buying, 12 months | −$118K | $62.8M (better) |
| Short interest, % of float | 10.4% | – |
Go deeper
- RXST stock overview
- RXST income statement
- RXST valuation and score
- STAA stock overview
- STAA income statement
- STAA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.